Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCD0M4
|
|||
| Drug Name |
Tinlarebant
|
|||
| Synonyms |
Tinlarebant; Tinlarebant [USAN]; LBS-008; BPN-14967; 63WI9S8P1M; UNII-63WI9S8P1M; WHO 11058; 1-(3-(4-(3,4-Difluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo(3,4-C)pyridin-6-yl)ethan-1-one; 1821327-95-0; Ethanone, 1-(3-((4-(3,4-difluoro-2-(trifluoromethyl)phenyl)-1-piperidinyl)carbonyl)-1,4,5,7-tetrahydro-6H-pyrazolo(3,4-C)pyridin-6-yl); TINLAREBANT [INN]; CHEMBL3967849; SCHEMBL17223028; BDBM249482; US9434727, 80; US9434727, 81; 1-(3-(4-(3,4-difluoro-2-(trifluoromethyl)phenyl)piperidine-1-carbonyl)-4,5-dihydro-1H-pyrazolo[3,4-c]pyridin-6(7H)-yl)ethanone
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Stargardt disease [ICD-11: 9B70; ICD-10: H35.5] | Phase 3 | [1] | |
| Company |
Belite Bio
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21F5N4O2
|
|||
| Canonical SMILES |
CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=C(C=C4)F)F)C(F)(F)F
|
|||
| InChI |
InChI=1S/C21H21F5N4O2/c1-11(31)30-9-6-14-16(10-30)27-28-19(14)20(32)29-7-4-12(5-8-29)13-2-3-15(22)18(23)17(13)21(24,25)26/h2-3,12H,4-10H2,1H3,(H,27,28)
|
|||
| InChIKey |
HAGSLCBZFRRBLS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Plasma retinol-binding protein (RBP4) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05244304) Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects. U.S.National Institutes of Health. | |||
| REF 2 | Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. Eur J Med Chem. 2021 Dec 15;226:113856. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.